Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Curr Opin Pharmacol. 2018 Apr;39:121-128. doi: 10.1016/j.coph.2018.04.005.
Prevalence of peripheral arterial disease in patients with coronary artery disease is considerably higher than in the general population. A graded increase in the risk of major cardiovascular events in a variety of clinical settings is associated with the number of arterial beds affected by peripheral arterial disease. This is not surprising, considering that both coronary artery disease and peripheral arterial disease are linked to a higher prevalence of cardiovascular risk factors and a greater incidence of atherosclerotic burden. Aggressive lipid lowering therapy is associated with less coronary and peripheral arterial disease progression and greater regression. On the contrary, blood pressure therapy should be carefully managed, considering the association of both high and low values of pressure with adverse outcomes.
患有冠状动脉疾病的患者中,周围动脉疾病的患病率明显高于普通人群。在各种临床环境中,随着受周围动脉疾病影响的动脉床数量的增加,主要心血管事件的风险呈分级增加。这并不奇怪,因为冠状动脉疾病和周围动脉疾病都与心血管危险因素的更高患病率和动脉粥样硬化负担的更高发生率有关。强化降脂治疗与较少的冠状动脉和周围动脉疾病进展和更大的消退相关。相反,应谨慎管理血压治疗,因为血压的高低值都与不良结局有关。